source
- Sellas cancer vaccine cuts death risk by 41% in late-stage AML trialSellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
- John Powers III named permanent director of NIH's National Institute of Allergy and Infectious DiseasesNIH's National Institute of Allergy and Infectious Diseases (NIAID) has finally filled its top leadership vacancy that has persisted since 2025. The institute had been led in an acting capacity by…